Figure 3.

Tumor growth suppressive effect of DFP‐10825 in a NCI‐N87 peritoneally disseminated mouse model. Luciferase‐expressing NCI‐N87 peritoneally disseminated model mice were injected with either DFP‐10825 (20 µg/mouse/d, five injections once every 3 d, i.p.) or S‐1 (3.5 mg tegafur/kg/d, 14 doses once every day, p.o.) from Day 7 post‐tumor implantation. A, Bioluminescent intensities of the disseminated tumors were calculated from the data imaged using in vivo imaging system at selected time points (Days 7, 23, 30, 37, and 45 post‐tumor implantation). The data are represented as the mean ± SD (n = 2‐3, *P < .05, **P < .01 vs control). B, Body weight change of the mice was monitored at selected time points. The data are represented as the mean ± SD